Antibodies binding to VEGF and il-1 beta and methods of use thereof
By developing a bispecific anti-VEGF/anti-IL-1β antibody containing VEGF and IL-1β complementary sites, the problem of lack of effective therapeutic antibodies in the prior art that binds VEGF and IL-1β simultaneously is solved, and efficient treatment of ocular vascular diseases and high stability are achieved.
CN119708249APending Publication Date: 2025-03-28F HOFFMANN LA ROCHE & CO AG
60 Cites 0 Cited by
Patent Information
- Application Number
- CN202411953347.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-21
- Filing Date
- 2019-12-20
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
There is a lack of effective therapeutic antibodies in the prior art that can bind both VEGF and IL-1β to treat ocular vascular diseases.
Method used
A bispecific anti-VEGF/anti-IL-1β antibody is developed that contains VEGF complement and IL-1β complement within a homologous pair of the variable light chain domain and the variable heavy chain domain to achieve high affinity binding to VEGF and IL-1β through specific amino acid residue combinations.
Benefits of technology
This antibody can efficiently bind VEGF and IL-1β, inhibit its binding to the corresponding receptor, significantly improve the therapeutic effect of ocular vascular diseases, and has high stability and appropriate viscosity suitable for ophthalmic applications.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to anti-VEGF / anti-IL-1 [beta] antibodies and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art